- Home
- PETZ vs FEMY Comparison
PETZ vs FEMY Comparison
Compare PETZ & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | FEMY |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | China | United States |
| Employees | 12 | N/A |
| Industry | Steel/Iron Ore | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 12.0M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PETZ | FEMY |
|---|---|---|
| Price | $1.13 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 8.1K | ★ 35.0K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.81 | $0.29 |
| 52 Week High | $1.83 | $6.29 |
Technical Indicators
Market Signals| Indicator | PETZ | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 43.75 |
| Support Level | $1.11 | $0.48 |
| Resistance Level | $1.23 | $4.78 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 13.01 | 5.57 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.